Lupin Acquires VISUfarma to Strengthen European Ophthalmology Presence

Lupin Limited has acquired VISUfarma, a European specialty pharmaceutical company focused on ophthalmology, from GHO Capital Partners. The transaction supports Lupin’s efforts to expand its presence in the European specialty pharmaceutical market and adds to its global ophthalmology portfolio.

Background on VISUfarma and Its Growth

VISUfarma was created in 2016 through the combination of founder-owned VISUfarma (Italy) and the European commercial operations of Nicox SA, a move facilitated by GHO Capital Partners. Since its formation, VISUfarma has expanded its operations across Italy, the United Kingdom, Spain, Germany, and France, developing a portfolio of more than 60 branded ophthalmic products.

These products address a range of front- and back-of-the-eye conditions, including dry eye disease, glaucoma, blepharitis, retinal health, and eyelid hygiene, as well as a selection of specialized nutraceuticals.

According to GHO Capital, the company has grown into a pan-European ophthalmology business with a diversified product offering. Andrea Ponti and Mike Turner of GHO Capital noted:

“Working closely with the VISUfarma management team, GHO Capital has transformed the company from a domestic Italian ophthalmic player into a unique pan-European business with established operations across key markets, a robust product portfolio covering the main disease areas impacting both the front- and back-of-the-eye, and the infrastructure to continue its growth trajectory.

Lupin’s Expansion Strategy in Europe

The acquisition is part of Lupin’s broader strategy to expand in Europe and strengthen its global specialty pharmaceutical segment, particularly in ophthalmology. The transaction was executed through Lupin’s wholly owned subsidiary Nanomi BV, giving the company direct access to established ophthalmology markets in Europe and a pipeline of therapies across multiple eye conditions.

Commenting on the acquisition, Vinita Gupta, CEO of Lupin, stated:

“We are delighted to welcome VISUfarma into the Lupin family. This acquisition strengthens our commitment to delivering innovative medicines to the patients and communities we serve. Beyond being immediately accretive, it also broadens our presence in Europe and further builds our specialty franchise in ophthalmology.”